The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...

GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a ...

Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle ...

Shares of GSK are seen rising 5% according to pre-market indications on Thursday after the British drugmaker agreed to pay up ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

GSK has agreed to pay up to $2.2 billion to settle most pending U.S. state court lawsuits claiming that a discontinued ...

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...

GSK agreed to pay $2.2 billion to 10 plaintiff firms over liability cases related to its discontinued heartburn medicine ...

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

GSK could still cause problems for the British firm: UBS. GlaxoSmithKline (GSK) saw its shares jump more than 6% after the ...